Markets

Chiasma (CHMA) Jumps: Stock Adds 5.6% in Session

Chiasma, Inc. ( CHMA ) was a big mover last session, as the company saw its shares rise roughly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 23.6% in the last one month.

The company has seen no estimate revisions over the past 7 days, and the Zacks Consensus Estimate is unchanged over the same time frame. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Chiasma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked biotechnology stock is Regeneron Pharmaceuticals, Inc. ( REGN ), sporting a Zacks Rank #1 (Strong Buy).

Is CHMA going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CHIASMA INC (CHMA): Free Stock Analysis Report

REGENERON PHARM (REGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

REGN CHMA

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More